C&CAUSES & WHAT WE KNOW
Causes & What We Know/November 17, 2026/3 min read

A New Player in Type 1 Diabetes: Understanding Carbamylation in Beta Cells

Scientists have identified a chemical modification called carbamylation that appears more frequently in insulin-producing cells during early Type 1 diabetes. This discovery may help explain how inflammatory signals damage these critical cells.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

  • Carbamylation—a chemical modification of proteins—occurs more often in beta cells of mice prone to Type 1 diabetes compared to non-diabetic mice
  • When pro-inflammatory signals attack beta cells, they trigger carbamylation of hundreds of proteins involved in energy production and insulin processing
  • Two key enzymes affected by carbamylation become less effective at their jobs, which could contribute to beta cell dysfunction
  • This research identifies a new mechanism that might explain how inflammation damages insulin-producing cells in Type 1 diabetes

What Is Carbamylation?

In Type 1 diabetes, the immune system mistakenly attacks insulin-producing beta cells in the pancreas. This attack is driven by inflammatory signals—chemical messengers that trigger widespread changes inside the cells. Scientists have long studied two well-known chemical modifications that occur during this process: phosphorylation and acetylation. But researchers recently turned their attention to a less-studied modification called carbamylation, which had been linked to other autoimmune diseases. The question was: could carbamylation also play a role in Type 1 diabetes?

Early Signs in Pre-Diabetic Mice

To investigate, scientists examined pancreatic tissue from NOD mice—a model commonly used to study Type 1 diabetes—at an early stage before diabetes develops (8-9 weeks old). They compared these mice to healthy CD1 mice. The difference was striking: pre-diabetic NOD mice had carbamylation present in 11% of their beta cells, while only 5% of beta cells in non-diabetic mice showed this modification. This suggests carbamylation increases as Type 1 diabetes begins to develop, hinting at a connection to the disease process.

A Widespread Response to Inflammatory Signals

To understand what happens when beta cells face inflammatory attack, researchers used a cell line derived from insulin-producing cells and exposed it to three pro-inflammatory signals: IFN-gamma, IL-1 beta, and TNF-alpha. These are the same chemical messengers at work in Type 1 diabetes. The results revealed that carbamylation affected an enormous number of proteins—284 carbamylated peptides from 222 different proteins were identified. These proteins were involved in multiple cellular functions, including energy metabolism, DNA replication, and protein synthesis.

Damage to Essential Beta Cell Functions

The most significant finding was what happened to two specific proteins. Aldolase A, an enzyme critical for the glycolytic pathway that generates energy in cells, became impaired by carbamylation. Similarly, carboxypeptidase E, an enzyme essential for processing and packaging insulin correctly, also lost function when carbamylated. When these enzymes don't work properly, beta cells struggle to produce energy and release insulin effectively—both fundamental to their survival and function. This suggests that carbamylation may be one mechanism explaining how inflammatory signals directly damage beta cells.

What This Means for Understanding Type 1 Diabetes

This research opens a new window into how Type 1 diabetes develops. While phosphorylation and acetylation have been studied extensively, carbamylation has largely been overlooked. By identifying carbamylation as a key player in inflammatory damage to beta cells, scientists have identified a potential new target for understanding—and possibly interrupting—the disease process. The findings are still at an early research stage and much more work is needed to fully understand carbamylation's role in humans with Type 1 diabetes, but this represents meaningful progress in uncovering the mechanisms underlying the condition.

Evidence label

Source: The Biochemical journal. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.